Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| At Rain, we're proud that we were able to move as quickly as we did to test the hypothesis in a robust trial, as we did for a global Phase 3 study, despite the results not being what we had hoped |
| Looking forward, we believe there are exciting opportunities ahead |
| And again, I think the expertise that the team demonstrated through the MANTRA, MANTRA-2 studies, we think is exemplary |
| Given these top line data for milademetan, we determined that Rain will be best positioned to achieve its business objectives by taking action to streamline operations, reprioritize its activities, and implement certain cost saving measures, including a reduction in force |
| We were able to implement those actions very quickly, resulting in substantial moderation of cash burn that will be apparent in the third quarter and beyond |
| Hope you're doing well and thanks for taking the questions |
| Rain anticipates that its quarter-end cash position will provide runway into year-end 2026 in the absence of a corporate transaction and partner financing |
| Although we won't comment on programs under diligence, there are a number of opportunities that could be of great fit for Rain, with fascinating technology and novel therapeutic strategies for patients |
| And if we can find an avenue that we think we can add value to, that's when it becomes more attractive than one of the other alternatives |
| Great |
| But at the current time, I think with my comments on the call, this is a unique time in biotech where there's a multitude of opportunities that are available to companies in our current position |
| Have a great day |
| Our corporate development team has been rapidly reviewing an extraordinary number of actionable opportunities to license or acquire clinical stage programs and technologies that may allow Rain to continue to try to make a difference for cancer patients |
| I think what we’d comment there is, we want to be able to leverage our clinical organization |
| We continue to believe that reactivating p53 is an important therapeutic strategy to add to the armamentarium of anti-cancer therapies |
| Anshul Dhankher Great, thank you |
| The second quarter was an important time at Rain Oncology as we provided the top line data readout on our Phase 3 global registrational trial for milademetan, our oral small molecule inhibitor of the MDM2-p53 complex in dedifferentiated liposarcoma or DD LPS |
| We thank you very much for participating and ask that you please disconnect your lines |
| Thanks |
| Thank you |
| Thank you |
| Thank you |
| Thank you, guys |
| Statement |
|---|
| It is no surprise that the challenging climate in biotech over the last few years has resulted in a number of interesting programs, companies, and technologies being underfinanced and often without strong cross departmental leadership |
| We also announced that we would suspend the enrollment of our second clinical study, the MANTRA-2 study |
| We reported that the Phase 3 for milademetan did not meet its primary endpoint |
| For the three months ended June 30, 2023, Rain reported enough loss of $22.1 million as compared to a net loss of $17.6 million for the same period in 2022 |
| I just want to highlight that in the second half of this year, 2023, you will see a significant reduction in cash runaway |
| So, in terms of the cash burn expense in Q3 onwards is going to be significantly lower compared to what you've seen in the first two quarters of this year and the prior year |
| Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in Rain’s most recent quarterly reports on Form 10-Q, and annual report on Form 10-K filed with the Securities and Exchange Commission and other SEC filings |
| And same for the RAD52 program, we're not moving that forward, and we stopped all investment over a year ago |
Please consider a small donation if you think this website provides you with relevant information